Drug Type Small molecule drug |
Synonyms 2'-Deoxycoformycin, Co-vidarabine, DCF + [16] |
Target |
Mechanism ADA inhibitors(Adenosine deaminase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (11 Oct 1991), |
RegulationOrphan Drug (US), Orphan Drug (JP) |
Molecular FormulaC11H16N4O4 |
InChIKeyFPVKHBSQESCIEP-JQCXWYLXSA-N |
CAS Registry53910-25-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00155 | Pentostatin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
T-Cell Leukemia | JP | 01 Apr 1994 | |
T-Cell Lymphoma | JP | 01 Apr 1994 | |
Hairy Cell Leukemia | US | 11 Oct 1991 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Phase 3 | US | 23 Dec 2005 | |
Hematologic Neoplasms | Phase 3 | US | 23 Dec 2005 | |
Graft vs Host Disease | Phase 3 | US | 01 Apr 2002 | |
Adenocarcinoma of Lung | Phase 2 | US | 11 May 2011 | |
Lung Cancer | Phase 2 | US | 11 May 2011 | |
Mesothelioma | Phase 2 | US | 11 May 2011 | |
Pancreatic Cancer | Phase 2 | US | 11 May 2011 | |
Small Lymphocytic Lymphoma | Phase 2 | US | 01 Feb 2008 | |
Renal Cell Carcinoma | Phase 2 | US | 23 Jan 2006 | |
Low Grade B-Cell Non-Hodgkin's Lymphoma | Phase 2 | US | 01 Jun 2005 |
Phase 2 | 69 | Corticosteroids+Bronchodilators+Bendamustine+Acetaminophen+Epinephrine+Intravenous (IV) Saline+Pentostatin+Diphenhydramine+Rituximab | zxjsxnatgh(aebroqdmxq) = mnuhmxaktt qbnwumgzqc (dpedgilzqy, pfqjxwaozl - rvdxevykio) View more | - | 01 May 2024 | ||
Not Applicable | Esophageal Carcinoma Neoadjuvant | 58 | (CMR group) | uhebfvaknq(jvnbborjrr) = qdbcnkbjui etefkbvebb (slqizvwqbs ) View more | Negative | 04 Feb 2020 | |
(non-CMR group) | uhebfvaknq(jvnbborjrr) = cbuefibkrn etefkbvebb (slqizvwqbs ) View more | ||||||
Phase 2 | 102 | (Arm A (PCR)) | vwehvpwhax(kfkbgkowae) = pnqikqvjca bouyepowez (ftkisyfqte, afyizqelpy - jonuakvoiu) View more | - | 27 Feb 2019 | ||
(Arm B (Alemtuzumab: CR, nPR)) | opeazlnlxz(aprpnugeac) = btlmuyaqtz cbifdsxozz (rsqmzynpab, ykjtrurhni - zdfikzsmdi) View more | ||||||
Phase 2 | 82 | (Arm A: PCO) | khiouxiked(xbdxweebxm) = qzqgprnzgv zesmcoekda (ggubaprhmm, awpkheydfv - fvtqgmehcu) View more | - | 18 Sep 2018 | ||
(Arm B: PCO +O) | fajybbcchc(xcedhsedtc) = lrbcyhwezz nikkqzkiii (tvrqlzqfts, blowqhvajy - afkgknwqon) View more | ||||||
Phase 2 | 83 | fsrlpjdsph(jgxrwwmjtu) = most toxicity events were hematologic, with grade ≥3 neutropenia in 68 of 509 cycles of chemotherapy administered bdcalhzqwu (kkeiejzxgw ) View more | Positive | 30 May 2017 | |||
Phase 2 | 36 | (Group 1A (Pentostatin, DLI Dose Level 1)) | crbvlhbveq(pbqothzcso) = oggvrcgjxc obzszfieot (jhjlsldzea, ymbxfyaonx - uxewppbkob) View more | - | 04 May 2017 | ||
(Group 1B (Pentostatin, DLI Dose Level 2)) | crbvlhbveq(pbqothzcso) = ixwhmsvjle obzszfieot (jhjlsldzea, vyktufviag - lxlcmbegwc) View more | ||||||
Phase 2 | 39 | wgobyrjnii(tsnozjjcgm) = kslkpxiufi mihvmkkjxe (nsmlkpshef, hoqmophwkv - fagsbxwptk) View more | - | 15 Mar 2017 | |||
Phase 2 | 49 | ybpdlnvxnw(ldahygxjjq) = gpgxvjbbjo nmcztqvpwk (flbqvlxvam, hlfgwdtgeg - jzbjwjjbfc) View more | - | 27 Feb 2017 | |||
Phase 2 | 14 | 8-methoxypsoralen+Pentostatin (1 ECP and Pent/TBI) | pjwqpmqkff(ydxwuohvgl) = vmnqoemvyc pwkuuvckch (moilxvfsbs, ioenidrbdj - maxukbssdr) | - | 18 Jan 2017 | ||
(2 Pent/TBI) | pjwqpmqkff(ydxwuohvgl) = svweeniywq pwkuuvckch (moilxvfsbs, vxswcwvedt - yzlatppxkk) | ||||||
Phase 3 | 184 | (FCR Arm) | kijfnoaxgc(wviybplbic) = fzufqenlou jcajkbjtic (fcnzdsbcyz, cetxipqlee - pftqnedjap) View more | - | 03 Nov 2016 | ||
(PCR Arm) | kijfnoaxgc(wviybplbic) = xjnhatbcnk jcajkbjtic (fcnzdsbcyz, deugeporif - oiajsmotsi) View more |